The Lung Cancer Drug Where Half the Patients Are Still Winning After 7 Years

For a patient population that lives in fear of the next brain MRI, that kind of protection is transformative.

Are We Allowed to Say "Cure" Yet?

Oncologists are famously cautious people. They've been burned too many times by promising data that didn't hold up. So it's telling that even cautious voices are starting to whisper the C-word, with caveats.

Dr. David Spigel, who discussed the data at ASCO, called the PFS "outstanding" and said, "We have not seen anything close to this" in advanced lung cancer. Dr. Ben Solomon and colleagues described it as "unprecedented long-term benefit." One oncology commentator put it more bluntly: "We may be approaching functional cure territory for some patients."

The conditional probability data support that optimism. Among patients who made it to two years without their cancer progressing, the chance of still being progression-free at year seven was roughly 79%. In other words, if the drug is working well at the two-year mark, the odds strongly favor it continuing to work for a very long time.

But there are important asterisks. These patients are still taking lorlatinib every day. We don't know what happens if they stop. Overall survival data remain immature because, frankly, not enough patients have died to run the statistical analysis. That's a good problem to have, but it means we can't yet draw the ultimate survival curve. And CROWN compared lorlatinib to crizotinib, a first-generation drug that most oncologists had already moved past. A head-to-head trial against alectinib (the previous standard) would be more definitive.

Living With the Drug, Not Just on It

Seven years of daily medication means seven years of side effects. Lorlatinib's safety profile is manageable, but it's not invisible. The biggest issues are high cholesterol and triglycerides, which show up in most patients and typically require statin therapy. Weight gain and swelling are common too.

Then there are the CNS effects: cognitive fog, mood changes, and occasionally speech difficulties. These tend to be mild or moderate, and the CROWN data show that most cases improved with dose adjustments. Importantly, the seven-year follow-up found no new safety signals beyond what was already known. The drug didn't reveal some hidden long-term toxicity lurking at year six. For patients weighing years of side effect management against years of cancer-free life, that tradeoff is usually pretty straightforward.

The Business of Not Dying

Pfizer isn't just sitting on good clinical data; it's sitting on a blockbuster. Lorlatinib generated roughly $1 billion in global revenue in 2025, growing approximately 45% year over year. In the first quarter of 2026, sales were up another 32%. At a time when Pfizer is trying to offset declining COVID revenue, lorlatinib has become one of the company's most strategically important growth engines.

The competitive landscape is shifting in its favor, too. Alectinib (Roche's second-generation ALK inhibitor) has been the global first-line standard for years, but lorlatinib is steadily stealing first-line prescriptions in the U.S., China, and other major markets. Brigatinib and ensartinib play more niche roles. With no generic competition until at least the late 2020s, Pfizer has clear runway ahead.

Seven-year data showing more than half of patients still benefiting from the drug is, to put it mildly, good marketing material.

Who This Matters For

ALK-positive lung cancer is rare, accounting for roughly 3 to 5% of all NSCLC cases. That translates to about 6,000 new patients per year in the U.S. and around 40,000 worldwide. These patients skew younger (median age around 50), are often never-smokers, and tend to be otherwise healthy. They're the people you'd least expect to get lung cancer.

For this specific population, lorlatinib is rewriting what a metastatic cancer diagnosis means. It's no longer necessarily a death sentence measured in months. For many, it's becoming a chronic condition managed with a daily pill, potentially for decades.

The Bottom Line

We're not ready to call it a cure. But when more than half of metastatic lung cancer patients are progression-free after seven years on a single oral drug, we're witnessing something the field has never seen before. The question is no longer whether lorlatinib works. It's how long the winning streak can last.

Merck Just Found a New Way to Outflank Pfizer's Vaccine Empire

The FDA just gave Merck's CAPVAXIVE vaccine a pediatric expansion for high-risk kids aged 2-17, cracking open a door that Pfizer's Prevnar franchise had locked shut. In the multibillion-dollar pneumococcal vaccine war, Merck's adult-optimized shot now has a foothold across the age spectrum.